Celecoxib (Celebrex) and CYP2C9 Pharmacogenomics

What Is Celecoxib?

Celecoxib (brand name Celebrex) is a selective COX-2 inhibitor NSAID widely prescribed for osteoarthritis, rheumatoid arthritis, and acute pain. Unlike non-selective NSAIDs such as ibuprofen, celecoxib selectively inhibits cyclooxygenase-2 (COX-2), which reduces the risk of gastrointestinal bleeding compared to traditional NSAIDs. However, celecoxib carries cardiovascular concerns at higher doses, a class effect shared by COX-2 selective agents.

What makes celecoxib relevant to pharmacogenomics is that it is primarily metabolized by CYP2C9, a cytochrome P450 enzyme with well-characterized genetic variants. Patients with reduced CYP2C9 function metabolize celecoxib more slowly, leading to higher drug exposure and an increased risk of adverse effects — a concern that can be anticipated through genotype testing.

Why Celecoxib Response Varies by Genetics

CYP2C9 is the primary metabolic pathway for celecoxib. The enzyme converts celecoxib into inactive metabolites that are then eliminated from the body. When CYP2C9 activity is reduced due to genetic variants, celecoxib is cleared more slowly, resulting in higher and more prolonged drug levels.

Poor metabolizers (those carrying two reduced-function alleles, such as *3/*3) can have 3-7 times higher celecoxib exposure compared to normal metabolizers. Intermediate metabolizers have moderately elevated levels. This increased exposure amplifies both the therapeutic effect and the risk of cardiovascular and gastrointestinal adverse events. Understanding this metabolic pathway is key to how pharmacogenomic testing can inform NSAID prescribing.

CYP2C9 and NSAID Metabolism

CYP2C9 genotype determines how efficiently celecoxib is metabolized. The common reduced-function alleles are *2 and *3, with *3 having a greater impact on enzyme activity. Phenotype categories and their implications for celecoxib:

• Normal Metabolizer (*1/*1): Standard CYP2C9 activity. Celecoxib is cleared at normal rates. Standard dosing is appropriate.
• Intermediate Metabolizer (*1/*2 or *1/*3): One reduced-function allele. Moderately elevated celecoxib levels compared to normal metabolizers. May warrant starting at the lowest effective dose.
• Poor Metabolizer (*2/*2, *2/*3, or *3/*3): Two reduced-function alleles. Significantly elevated celecoxib levels and the highest risk of dose-dependent adverse effects.

Notably, the same gene that influences warfarin dosing affects celecoxib metabolism. If you carry CYP2C9 reduced-function variants, this is relevant to both medications. See our warfarin page for details on CYP2C9 and anticoagulant therapy. For a plain-language explanation of how reduced-function genotypes affect drug processing, see what does poor metabolizer mean.

CPIC Guideline Summary

The CYP2C9-celecoxib interaction has a CPIC Level A classification — the strongest evidence level. The CPIC NSAID guideline recommends:

• Normal Metabolizer (*1/*1): Standard celecoxib prescribing. No genotype-based adjustments needed.
• Intermediate Metabolizer (*1/*2 or *1/*3): Consider initiating therapy at the lowest effective dose. Monitor for cardiovascular and GI adverse events.
• Poor Metabolizer (*2/*2, *2/*3, or *3/*3): Consider half the lowest recommended dose or an alternative analgesic that is not CYP2C9-dependent (e.g., acetaminophen).

Cardiovascular risk should be considered alongside CYP2C9 genotype when evaluating celecoxib therapy. Higher drug exposure in poor metabolizers may compound dose-dependent cardiovascular risk, making genotype-guided dose reduction or alternative selection particularly relevant in patients with cardiovascular risk factors.

Clinical Context and Evidence

Kirchheiner et al. (2003; PMID: 12900880) demonstrated that CYP2C9 poor metabolizers have substantially elevated celecoxib AUC (area under the curve), confirming the pharmacokinetic basis for genotype-guided dosing. Poor metabolizers showed significantly slower clearance and higher peak concentrations compared to normal metabolizers.

The FDA-approved celecoxib label includes pharmacogenomic information noting that CYP2C9 poor metabolizers may have higher than expected plasma concentrations. The CPIC NSAID guideline, which covers celecoxib alongside other CYP2C9- metabolized NSAIDs, synthesizes this evidence into actionable prescribing recommendations based on CYP2C9 genotype.

Understanding Your Results

If you have raw DNA data from 23andMe, AncestryDNA, or another consumer service, DecodeMyBio can determine your CYP2C9 diplotype and phenotype and report whether celecoxib is flagged as a drug-gene interaction. Your Medication Safety Report will include your CYP2C9 diplotype, function category, and the CPIC recommendation for celecoxib. You can view a sample report to see the format.

NSAID prescribing involves balancing pain relief against potential adverse effects. If your report identifies reduced CYP2C9 function, this does not mean you must avoid celecoxib entirely — dose adjustment or alternative analgesics may be appropriate. Always discuss results with your healthcare provider. See our methodology and limitations pages for important context about consumer-grade analysis. To see how DecodeMyBio compares to other pharmacogenomic testing options, visit our testing comparison page.

Related Resources

• CYP2C9 gene — variants, phenotypes, and drug metabolism
• Warfarin and CYP2C9/VKORC1 — same gene, different medication
• What to do with your 23andMe raw data

Frequently Asked Questions